- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe-09-01-2009
Pharmaceutical Technology Europe
The combination drugs debate: unstable and unpatentable
September 01, 2009
Formulation
21
9
Combination products have been researched and administered for many years, some successfully and others not.
Expansion plan
September 01, 2009
Outsourcing Review
21
9
In the current slow growth environment, service providers are looking to tactical expansions, as well as more ambitious strategic service expansions.
The combination drugs debate: Incompatibility problems can be overcome
September 01, 2009
Formulation
21
9
Combining drugs with synergistic mechanisms of action yields some indisputable benefits; improved efficacy, reduced dosing, enhanced patient compliance, to name just a few.
Integrating PAT into biopharmaceutical research: a case study
September 01, 2009
21
9
This case study describes the implementation of process analytical technology on the cultivation process step of a whole-cell vaccine against whooping cough disease.
What to consider when expanding businesses into North America
September 01, 2009
Business
21
9
Increase your chances of success in the biggest market in the world.
Is another ODT excipient necessary?
September 01, 2009
Formulation
21
9
Parteck ODT is a newly introduced ready-to-use excipient for fast melt tablets.
Belgium: Will its enviable geographic position continue to ensure success in pharma?
September 01, 2009
Special Report
21
9
Belgium is one of the largest centres for pharmaceutical distribution and has the second highest number of pharma exports per capita worldwide.
Embryonic stem cells: the moral dilemma of patentability and funding
September 01, 2009
Regulatory
21
9
Human embryonic stem cells are of immense interest to researchers because of their ability to potentially develop into any kind of tissue.
The benefits of risk-based analyses during system validation
September 01, 2009
Validation
21
9
When validating automated systems from third-party providers, using the V model and failure modes effects and criticality analysis (FMECA) early in the process can help.
Strength in numbers
September 01, 2009
21
9
Merger, union, alliance, partnership, collaboration: five words that ultimately suggest the strengthening of something.
Successful packaging of aseptically prefilled products
September 01, 2009
Ask the Expert
21
9
Why correctly calibrating a drug with its packaging is the key to success.
The influence of superdisintegrant choice on the rate of drug dissolution
September 01, 2009
Formulation
21
9
The addition of superdisintegrants to oral solid dosage forms can improve disintegration and, in turn, drug dissolution.
The state of validation in the European Union
September 01, 2006
Validation
21
9
Since the formation of the European Union (EU) in 1993, each member state has brought along its own regulatory baggage, namely the standards and regulations that their companies are formally required to comply with. These standards and regulations still apply for any pharmaceutical products a native manufacturer decides to market within their homeland. When the same manufacturer markets its pharmaceutical products to consumers in other EU member states, the regulatory directives of the European Commission and the European Agency for the Evaluation of Medicinal Products (EMEA) apply as well.
Digital Revolution
September 01, 2006
21
9
It's been a while since I last wrote my last editor's comment - a combination, during the last few months, of attending a variety of industry events (as the conference and exhibition season peaked before the summer) and being on holiday. I apologize for the poor excuses, but it's certainly better than saying the dog ate my homework.